Submission for OMB Review; Comment Request; Correction, 7525 [E8-2373]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 27 / Friday, February 8, 2008 / Notices
incorporated places also constitute
MCDs.
Nonvisible feature—A map feature
that is not visible on the ground, such
as a city or county boundary through
space, a property line running through
space, a short line-of-sight extension of
a road to another visible feature, or a
point-to-point line of sight.
Visible feature—A map feature that
can be seen on the ground, such as a
road, railroad track, major above-ground
transmission line or pipeline, river or
stream, shoreline, fence, sharply defined
mountain ridge, or cliff. A nonstandard
visible feature is a feature that may not
be clearly defined on the ground (such
as a ridge), may be seasonal (such as an
intermittent stream), or may be
relatively impermanent (such as a
fence). The Census Bureau generally
requests verification that nonstandard
features pose no problem in their
location during fieldwork by Census
Bureau staff.
Executive Order 12866
This notice has been determined to be
not significant under Executive Order
12866.
Paperwork Reduction Act
This program notice does not
represent a collection of information
subject to the requirements of the
Paperwork Reduction Act, 44 U.S.C.,
Chapter 35.
Dated: February 5, 2008.
Steve H. Murdock,
Director, Bureau of the Census.
[FR Doc. E8–2348 Filed 2–7–08; 8:45 am]
BILLING CODE 3510–07–P
DEPARTMENT OF COMMERCE
Bureau of Economic Analysis
Submission for OMB Review;
Comment Request; Correction
Bureau of Economic Analysis
(BEA), Department of Commerce.
This notice corrects the notice
published on February 1, 2008, Volume
73, Number 22, page 6114. The
following items are corrected and
replaced—
Title: Biomedical Research and
Development Price Index (BRDPI)
Survey.
OMB Control Number: 0608–0069.
All other information stated in the
February 1, 2008 notice remains
effective.
pwalker on PROD1PC71 with NOTICES
AGENCY:
VerDate Aug<31>2005
17:11 Feb 07, 2008
Jkt 214001
Dated: February 5, 2008.
Gwellnar Banks,
Management Analyst, Office of the Chief
Information Officer.
[FR Doc. E8–2373 Filed 2–7–08; 8:45 am]
BILLING CODE 3510–06–P
DEPARTMENT OF COMMERCE
Bureau of Industry and Security
Action Affecting Export Privileges:
AR–AM Medical Services LLC; In the
Matter of AR–AM Medical Services
LLC; Case No. 06–08
Order
The Office of Antiboycott
Compliance, Bureau of Industry and
Security, U.S. Department of Commerce
(‘‘BIS’’), having determined to initiate
an administrative proceeding pursuant
to Section 11(c) of the Export
Administration Act of 1979, as amended
(50 U.S.C. 2401–2420 (2000)) (the
‘‘Act’’) 1 and the Export Administration
Regulations (currently codified at 15
CFR Parts 730–774 (2007) (the
‘‘Regulations’’), against AR–AM Medical
Services LLC (‘‘AR–AM’’), a domestic
concern, based on allegations set forth
in the Proposed Charging Letter, dated
April 17, 2006, that alleged that AR–AM
committed three violations of the
Regulations;
*
*
*
*
*
Specifically, the charges are:
1. Three Violations of 15 CFR
760.2(d)—Furnishing Information about
Business Relationships With Boycotted
Countries or Blacklisted Persons: During
the years 2001 and 2002, AR–AM
engaged in transaction(s) involving the
sale and/or transfer of goods or services
(including information) from the United
States to Syria. In connection with these
activities, on three occasions, AR–AM,
with intent to comply with, further or
support an unsanctioned foreign
boycott, furnished information
concerning its or another person’s
business relationships with or in a
1 From August 21, 1994 through November 12,
2000, the Act was in lapse. During that period, the
President, through Executive Order 12924, which
had been extended by successive Presidential
Notices, the last of which was August 3, 2000 (3
CFR 2000 Comp. 397 (2001)), continued the
Regulations in effect under the International
Emergency Economic Powers Act (50 U.S.C. 1701–
1706 (2000)) (‘‘IEEPA’’). On November 13, 2000, the
Act was reauthorized by Pub. L. 106–508 (114 Stat.
2360 (2000)) and remained in effect through August
20, 2001. Since August 21, 2001, the Act has been
in lapse. Executive Order 13222 of August 17, 2001
(3 CFR 2001 Comp 783 (2002)), which has been
extended by successive Presidential Notices, the
most recent of which was August 15, 2007 (72 FR
46137 (August 16, 2007)), continues the Regulations
in effect under IEEPA.
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
7525
boycotted country, an activity
prohibited by Section 760.2(d) of the
Regulations, and not excepted.
BIS and AR–AM having entered into
a Settlement Agreement pursuant to
Section 766.18(a) of the Regulations
whereby the parties have agreed to settle
this matter in accordance with the terms
and conditions set forth therein and the
terms of the Settlement Agreement
having been approved by me;
It is therefore ordered that:
First, a civil penalty of $7,200 is
assessed against AR–AM. Payment shall
be suspended for a period of two years
from the date of entry of this Order and
thereafter shall be waived, provided
that, during the period of suspension,
AR–AM has committed no violation of
the Act and Regulations or any order
issued thereunder.
Second, for a period of two years from
the date of entry of this Order, AR–AM
Medical Services LLC (Great Neck, New
York) (‘‘Denied Person’’) may not
participate, directly or indirectly, in any
way in any transaction involving any
commodity, software or technology
(collectively, ‘‘item’’) exported or to be
exported from the United States to
Bahrain, Iraq, Kuwait, Lebanon, Libya,
Oman, Qatar, Saudi Arabia, Syria, the
United Arab Emirates or the Republic of
Yemen (collectively, the ‘‘Territory’’)
that is subject to the Regulations, or in
any other activity relating to the
Territory that is subject to the
Regulations, including, but not limited
to:
A. Applying for, obtaining, or using
any license, License Exception, or
export control document, relating to the
Territory;
B. Carrying on negotiations
concerning, or ordering, buying,
receiving, using, selling, delivering,
storing, disposing of, forwarding,
transporting, financing, or otherwise
servicing in any way, any transaction
involving any item exported or to be
exported fro the United States to the
Territory that is subject to the
Regulations, or in any other activity
relating to the Territory subject to the
Regulations; or
C. Benefitting in any way from any
transaction involving any item exported
or to be exported from the United States
to the Territory that is subject to the
Regulations, or in any other activity
relating to the Territory subject to the
Regulations.
Third, no person may, directly or
indirectly, do any of the following:
A. Export or reexport to or on behalf
of the Denied Person any item subject to
the Regulations from the United States
to the Territory;
E:\FR\FM\08FEN1.SGM
08FEN1
]]>Agencies
[Federal Register Volume 73, Number 27 (Friday, February 8, 2008)]
[Notices]
[Page 7525]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-2373]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Bureau of Economic Analysis
Submission for OMB Review; Comment Request; Correction
AGENCY: Bureau of Economic Analysis (BEA), Department of Commerce.
This notice corrects the notice published on February 1, 2008,
Volume 73, Number 22, page 6114. The following items are corrected and
replaced--
Title: Biomedical Research and Development Price Index (BRDPI)
Survey.
OMB Control Number: 0608-0069.
All other information stated in the February 1, 2008 notice remains
effective.
Dated: February 5, 2008.
Gwellnar Banks,
Management Analyst, Office of the Chief Information Officer.
[FR Doc. E8-2373 Filed 2-7-08; 8:45 am]
BILLING CODE 3510-06-P
